Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial With Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

GlobeNewswire11/13 22:00

Creative Medical Technology Holdings Third Quarter 2024 Earnings: US$0.75 Loss per Share (Vs US$1.02 Loss in 3Q 2023)

Yahoo Finance11/10 22:19

クリエイティブ・メディカル・テクノロジー・ホールディングス | 10-Q：Q3 2024 四半期報告書

SEC11/09 05:50

Creative Medical Technology Files to Sell 0.83M Shares of Common Stocks by Selling Shareholders

Seeking Alpha11/09 05:41

Creative Medical Technology Files Patent For "AI Enhanced Real-Time Biological Optimization And Health Monitoring For Space Travel"

Benzinga11/08 02:22

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Benzinga10/23 20:07